What is QurAlis?
QurAlis is at the forefront of developing next-generation precision medicines targeting amyotrophic lateral sclerosis (ALS) and other neurodegenerative conditions. Leveraging genetically validated targets, the company utilizes proprietary platforms and unique biomarkers to design drugs that directly address disease-causing genetic alterations. Founded by a distinguished team of neurodegenerative biologists from Harvard Medical School and Harvard University, QurAlis is actively progressing a robust pipeline of antisense oligonucleotide and small molecule programs, with a particular focus on sub-forms of ALS that represent the majority of patient cases.
How much funding has QurAlis raised?
QurAlis has raised a total of $150M across 3 funding rounds:
Series A
$42M
Series B
$88M
Debt
$20M
Series A (2020): $42M with participation from MP Healthcare Venture Management, Mitsui Global Investment, Mission BioCapital, Sanford Biosciences, Droia Ventures, LS Polaris Innovation Fund, INKEF Capital, Amgen Business Development, Dolby Family Ventures, and Dementia Discovery Fund
Series B (2023): $88M led by Sanofi Ventures
Debt (2025): $20M, investors not publicly disclosed
Key Investors in QurAlis
Sanofi Ventures
Sanofi Ventures is the corporate venture capital arm of Sanofi, focusing on early-stage biotech and digital health companies with innovative ideas and transformative new products and technologies of strategic interest to Sanofi, including oncology, immunology, and rare diseases.
MP Healthcare Venture Management
MP Healthcare Venture Management is a Boston-based life science venture capital firm that collaborates with healthcare entrepreneurs to develop novel technologies and therapeutics, focusing on building the life science companies of tomorrow.
Mitsui Global Investment
Mitsui & Co. Global Investment, Inc. specializes in guiding innovative entrepreneurs by providing not just financial support but also strategic guidance to help them reach the global stage, with a focus on partnering with exceptional teams to reinvent industries and improve human welfare.
What's next for QurAlis?
The recent major strategic investment positions QurAlis for accelerated development and potential commercialization of its innovative therapies. This capital will likely fuel further clinical trials, expand research and development efforts, and strengthen the company's operational capacity. The company's focus on genetically validated targets and proprietary platforms suggests a strategy aimed at achieving significant breakthroughs in treating complex neurodegenerative diseases, potentially leading to new therapeutic standards and market leadership in this critical healthcare sector.
See full QurAlis company page
